
Considering a ‘designer dog'? This study might make you think again
'Designer dogs' are more likely to suffer from diarrhoea than other breeds, a study has found.
Trendy dogs that are hybrids between poodles and other breeds are increasingly popular, owing to a belief they have no health problems and a good temperament, as well as being aesthetically appealing.
But a study of more than two million dogs in the UK has revealed the cavapoo and cockapoo are among six breeds with a heightened chance of going to the vet with acute diarrhoea.
This likely comes from inherited genetics of the miniature poodle, the common ancestor of both of these popular hybrids, which is the breed most prone to the condition.
Miniature poodles are 2.17 times as likely to be seen by a vet for the condition than a standard cross-breed, while cavapoos are twice as likely and cockapoos 1.36 times more likely.
Overall, all designer dogs, which includes other portmanteau types such as the labradoodle, were found to be 34 per cent more likely to have the issue.
Cockapoos are now the most popular dog in the UK, behind the trusty family stalwart of the labrador retriever, and a previous study found they are no more sickly than other crosses.
However, the latest study from the Royal Veterinary College (RVC) found these popular puppies actually appear to have a predisposition to stomach problems.
'Every breed is by definition unique – that is what makes it a recognisable breed that differs to other dogs,' said Dr Dan O'Neill, Associate Professor in Companion Animal Epidemiology at RVC, and the study's lead author.
'Coming with that will be a unique disorder profile, with some disorders at higher risk and some at lower risk. The overall health of the breed is then the balance of the higher and lower risks.
'And this new evidence published today does suggest that diarrhoea is a higher risk in designer crosses overall – many of these are poodle crosses.'
He adds that the miniature poodle's high risk likely means there is an inherited component from this animal if it parents a cross.
'Dreaded doggy poonami'
But the authors say that the findings could also reflect that owners of these higher risk dog breeds could be feeding their animals food that upsets their stomach or are more likely to take their pet to the vets with the issue.
And because poodle-cross owners are often told that these animals are less prone to getting sick, this could make them more complacent in what they provide as food and also make them more likely to visit the vets if something does go wrong.
'Perhaps a prior belief in their better health may mean that owners are less careful with dietary control,' said Dr O'Neill. 'So it could paradoxically be the belief in health that causes the disease.'
'The bottom line is that anyone thinking of acquiring a poodle designer cross-breed should be aware of the increased risk of diarrhoea.
'Perhaps plan in advance and be very careful with consistent diet in terms of the timing of feeding, the volume of feeding, and consistency in the type of food fed. Having advance awareness of the risk can hopefully prevent diarrhoea even happening.'
The study used VetCompass data, which collects vet records from participating practices in the UK, and it found 1,835 confirmed cases of acute diarrhoea in 2019, which is around one in 12 dogs.
Half of these animals also had vomiting issues at the same time and a quarter had reduced appetite and lethargy.
While short-faced dogs like bulldogs, pugs and boxers often have a litany of health issues, diarrhoea is not one of them, the study shows.
These so-called brachycephalic breeds are collectively 20 per cent less likely to have diarrhoea than an average mongrel, while dogs with particularly long snouts such as greyhounds or borzoi, are 25 per cent more likely to have the issue.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
21 minutes ago
- The Independent
Women's Prize for Fiction ‘greatest honour' as an intersex woman, says winner
The winner of the Women's Prize for Fiction has said the award is 'the greatest honour of my life as a woman' as she reflected on her experience growing up intersex. Dutch author Yael van der Wouden won the accolade for her debut novel, The Safekeep, and used her winner's speech to champion the trans community, who have 'changed the system' and 'fought for health care'. The book, which explores repressed desire and the unresolved aftermath of the Holocaust in post-Second World War Netherlands, was described as an 'astonishing debut' by the head of the judges. The ceremony, held in central London on Thursday, saw the non-fiction prize awarded to physician Dr Rachel Clarke for The Story Of A Heart, which explores the human experience behind organ donation. In her winner's speech, after thanking the judges, van der Wouden said: 'I was a girl until I turned 13, and then, as I hit puberty, all that was supposed to happen did not quite happen. 'And if it did happen, it happened too much, and all at once my girlhood became an uncertain fact. 'I won't thrill you too much with the specifics, but the long and the short of it is that, hormonally, I'm intersex. 'This little fact defined my life throughout my teens, until I advocated for the health care that I needed. 'The surgery and the hormones that I needed, which not all intersex people need. Not all intersex people feel at odds with their gender presentation. 'I mention the fact that I did, because in the few precious moments here on stage, I am receiving, truly, the greatest honour of my life as a woman, presenting to you as a woman, and accepting this Women's Prize. 'And that is because of every single trans person who's fought for health care, who changed the system, the law, societal standards, themselves. I stand on their shoulders.' The NHS website says intersex, or differences in sex development (DSD), is a group of rare conditions involving genes, hormones and reproductive organs that mean a person's sex development is different to most. In contrast, people who are transgender identify as a gender separate to the sex they were born in and sometimes go through gender-affirming surgery. Van der Wouden's novel follows Isabel, a young woman whose life in solitude is upended when her brother's girlfriend Eva comes to live in their family house in what turns into a summer of obsession, suspicion and desire. The chairwoman of the judges for the fiction prize, writer Kit de Waal, said: 'This astonishing debut is a classic in the making, a story to be loved and appreciated for generations to come. Books like this don't come along every day.' Van der Wouden will receive £30,000 and a limited-edition bronze statuette known as the Bessie, which was created and donated by artist Grizel Niven. The judging panel for the Women's Prize for Fiction included novelist and journalist Diana Evans, author and journalist Bryony Gordon, writer and magazine editor Deborah Joseph, and musician and composer Amelia Warner. Clarke said she has 'literally been a feminist since I was too young to know what that word even meant', as she collected her award. The physician's book recounts two family stories, documenting how medical staff take care of nine-year-old Kiera in her final hours after a car accident, while offering a new life to nine-year-old Max who is suffering from heart failure from a viral infection. Clarke, who is behind the books Breathtaking and Your Life In My Hands: A Junior Doctor's Story, will receive £30,000 and a limited-edition piece of art known as the Charlotte, both gifted by the Charlotte Aitken Trust. The judging panel for the non-fiction prize included writer and broadcaster Dr Leah Broad, whose work focuses on women's cultural history, and novelist and critic Elizabeth Buchan. Previous winners of the fiction prize include Tayari Jones for An American Marriage and Madeline Miller for The Song Of Achilles, while the first non-fiction prize was awarded last year to Naomi Klein for Doppelganger: A Trip Into The Mirror World. The awards were announced by the Women's Prize Trust, a UK charity that aims to 'create equitable opportunities for women in the world of books and beyond'.


Press and Journal
29 minutes ago
- Press and Journal
Nappies cut ruled out as London-based experts drafted in to help NHS Grampian save millions
Health bosses have voted against plans to slash spending on newborn tots amid fears scrapping hospital nappies 'would do more harm than good'. A shock dossier earlier this week revealed a range of services across the north-east could be axed or reduced to save the health board £23 million. This included halting cancer treatment and elective surgeries on public holidays and even stopping giving out disposable nappies for most newborn babies. The proposed cost-cutting measures would have impacted expectant mums at maternity wards in Aberdeen, Inverurie, Peterhead and Elgin. It comes as NHS Grampian bosses scramble to recoup millions of pounds after officially becoming the most broke health board in Scotland. They currently have a staggering £68m overspend that they aim to reduce to £45m in the next 12 months. And now, external experts have been drafted in to help them balance the books. Government officials haven hired London-based advisors KPMG to crunch the numbers and help NHS Grampian come up with an expansive savings plan. They say the cash crisis within the health board has escalated to the point where there is a need for experts to intervene amid concerns over failing to improve services. Adam Coldwells reassured board members that NHS Grampian will still be 'absolutely in charge' of the recovery plan and the changes they implement further down the line. However, the external body will be there to monitor their progress, give advice on possible additional savings the board might have missed and 'hold them to account'. The interim chief executive said this is a necessary measure to turn the health board's fortunes around as 'the scale of the [financial] challenge is significant'. And he stressed this would be a good opportunity to learn and improve. He added: 'Clearly it's an extremely serious issue and relates primarily to our financial position, which as a board we've been working on for the last two years. 'We've certainly struggled to find the scale of savings that we need to. 'I'm optimistic this external support from an organisation, who has done this lots of times, will be able to find things that we've simply not been able to identify ourselves.' Members of the NHS Grampian board were later presented with a detailed report outlining 79 cost-cutting measures which will be implemented within the next year. Health bosses admit about a dozen of those could have direct impact on vulnerable patients – with a range of medical services no longer taking place on public holidays. This would affect non-emergency surgeries and diagnostic tests, as well as cancer treatments such as chemotherapy and radiation therapy. Routine test results will also be given by phone or letter, with face-to-face appointments taking place only when essential. The aim is to cut down on overtime pay. Board member Derick Murray questioned whether they are not 'taking a step back' by reducing these services. But interim director of people and culture, Philip Shipman, said running services on public holidays is 'incredibly expensive' so that's a good place to make a saving. Dr Colette Backwell later also reminded fellow board members that the recovery plan they have been presented with is a necessity rather than a choice. 'The Scottish Government is asking us to find more savings so we have to go along with that,' she said. Staff at pharmacies will also be taking a day off on public holidays from now on. Members raised concerns this could result in people not getting the treatment they need in a timely manner or being missed altogether. Area clinical forum chairman Mark Burrell admitted other health committees have had similar worries too. However, he reassured that there is a 'robust evaluation' under way so that 'patients do not suffer' at the hands of the proposed changes. 'This is kept under very close review,' Mr Burrell added. One of the proposed measures was, however, scratched from the plans amid fears it 'would not be supportive of vulnerable parents'. Board chairwoman Alison Evison raised concerns that if they stop giving out nappies at hospitals, parents might end up without any supplies at an already stressful time. This option would have essentially saved them around £8,000 per year. But Mrs Evison didn't think 'such a small' amount would justify the impact of going ahead with the proposals. She said: 'This saving has huge implications for certain people who are in need of that kind of support when they're coming to hospital. 'And yet, the saving associated with it is actually relatively small. 'Sometimes people will be coming to a hospital to have a baby when they are not expecting it at that point in time. It's a case of just not being prepared. 'So I think we are actually trying to make a saving which is going to be more negative than supportive.' All of the other proposals were given the green light, however, with a more detailed report being presented to the board in October.


The Independent
an hour ago
- The Independent
NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside
Blood cancer patients in England are set to be among the first in the world to access a pioneering "Trojan horse" treatment, health officials have announced. The targeted therapy, belantamab mafodotin, also known as Blenrep, has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, according to studies. Approximately 1,500 patients annually with multiple myeloma, an incurable bone marrow cancer, are expected to benefit from this new treatment. The National Institute for Health and Care Excellence (Nice) has approved Blenrep, manufactured by GlaxoSmithKline, for use within the NHS. NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be available to patients whose cancer has advanced or has not responded to initial treatments. Administered as an infusion every three weeks alongside other cancer drugs, this antibody drug targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'